| GTO ID | GTC3306 |
| Trial ID |
NCT05681351
|
| Disease |
Severe Hypertriglyceridemia
|
| Altered gene | APOC3 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | Olezarsen|ISIS 678354|IONIS-APOCIII-LRx|AKCEA-APOCIII-LRx |
| Co-treatment | Clopidogrel |
| Phase | Phase3 |
| Recruitment status | Recruiting |
| Title | An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia (SHTG) |
| Year | 2022 |
| Country | Australia|Bulgaria|Canada|Czechia|Denmark|France|Hungary|Israel|Italy|Netherlands|New Zealand|Norway|Poland|Slovakia|South Africa|Spain|Sweden|Turkey|United Kingdom|United States |
| Company sponsor | Ionis Pharmaceuticals, Inc. |
| Other ID(s) | ISIS 678354-CS15|2022-501999-26-00 |